{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:11:09Z","timestamp":1777957869166,"version":"3.51.4"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dedifferentiated liposarcoma (DDLPS) is a malignant mesenchymal tumor. While paraneoplastic leukemoid reaction (PLR) has been sporadically reported in DDLPS, its coexistence with severe anemia and thrombocytopenia, constituting a severe cytokine release syndrome (CRS), is exceedingly rare and presents a significant diagnostic and therapeutic challenge.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 56-year-old male with recurrent retroperitoneal well-differentiated liposarcoma presented with high fever, profound leukocytosis (WBC up to 43\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L), severe anemia (Hb 30 g\/L), and thrombocytopenia (platelets 10\u00d710\n                      <jats:sup>9<\/jats:sup>\n                      \/L), which precluded immediate surgery. Extensive workup ruled out infection and hematological malignancies. The clinical picture was consistent with a tumor-induced CRS, evidenced by markedly elevated interleukin-6 (IL-6) and C-reactive protein (CRP). Following a multidisciplinary discussion, the patient received intravenous tocilizumab (an IL-6 receptor antagonist) and methylprednisolone. His fever resolved rapidly, and hematological parameters improved significantly, facilitating successful tumor resection. Postoperative pathology confirmed DDLPS. All paraneoplastic symptoms and laboratory abnormalities normalized after surgery. However, at the second follow-up, tumor recurrence was observed along with a marked elevation of the WBC, which again decreased following the subsequent surgical resection.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case highlights that DDLPS can trigger CRS, which manifests with clinical features mimicking severe infection and leading to critical cytopenias that complicate surgical management. IL-6 pathway blockade with agents such as tocilizumab may be an effective bridging therapy to stabilize the systemic inflammatory state and create a safe window for surgical intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1762067","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:17:26Z","timestamp":1777954646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Tocilizumab as a novel bridging therapy for surgery in dedifferentiated liposarcoma complicated by paraneoplastic leukemoid reaction, severe anemia, and thrombocytopenia: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Jinjin","family":"Li","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Chongqing Traditional Chinese Medicine Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanshan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pathology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengqiang","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.02.006","article-title":"Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review","volume":"36","author":"Thway","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s112580","article-title":"Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas","volume":"9","author":"De Vita","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11864-020-0705-7","article-title":"Dedifferentiated liposarcoma: Systemic therapy options","volume":"21","author":"Gahvari","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102846","article-title":"Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statement","volume":"131","author":"Haddox","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71129","article-title":"Surgical management of retroperitoneal liposarcoma: Opportunities for multimodality treatment, including systemic therapy","volume":"14","author":"Sun","year":"2025","journal-title":"Cancer Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s40164-024-00540-4","article-title":"Role of CDK4 as prognostic biomarker in soft tissue sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment","volume":"13","author":"Vanni","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2019.01.002","article-title":"Paraneoplastic syndromes: Definitions, classification, pathophysiology and principles of treatment","volume":"36","author":"Henry","year":"2019","journal-title":"Semin Diagn Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.1997.tb04556.x","article-title":"Dedifferentiated liposarcoma with an inflammatory Malignant fibrous histiocytoma-like component presenting a leukemoid reaction","volume":"47","author":"Hisaoka","year":"1997","journal-title":"Pathol Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-5-131","article-title":"Dedifferentiated liposarcoma with leukocytosis. A case report of G-CSF-producing soft-tissue tumors, possible association with undifferentiated liposarcoma lineage","volume":"5","author":"Sakamoto","year":"2007","journal-title":"World J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2016.07.007","article-title":"Leukocytosis and leukemia","volume":"43","author":"Widick","year":"2016","journal-title":"Prim Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24480","article-title":"Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study","volume":"115","author":"Granger","year":"2009","journal-title":"Cancer"},{"key":"B12","article-title":"Evaluation of patients with leukocytosis","volume":"92","author":"Riley","year":"2015","journal-title":"Am Fam Physician"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2762-19","article-title":"G-CSF-producing undifferentiated pleomorphic sarcoma adjacent to the ascending colon and in the right iliopsoas muscle: A case report and review of the literature","volume":"58","author":"Kazama","year":"2019","journal-title":"Intern Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e258298","DOI":"10.3324\/haematol.2014.112813","article-title":"Dedifferentiated liposarcoma with heterologous rhabdomyosarcomatous differentiation in the bone marrow","volume":"16","author":"Scott","year":"2023","journal-title":"BMJ Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4103\/wjnm.wjnm_80_20","article-title":"Diffuse bone marrow uptake related to granulocyte colony-stimulating factor-producing maxillary sinus carcinoma on 4-borono-2-(18)F-fluoro-L-phenylalanine positron emission tomography\/computed tomography","volume":"20","author":"Kusumahstuti","year":"2021","journal-title":"World J Nucl Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26651","article-title":"Thrombocytopenia, anasarca, and severe inflammation","volume":"97","author":"Montazeripouragha","year":"2022","journal-title":"Am J Hematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042921-112837","article-title":"Cytokine storm syndrome","volume":"74","author":"Cron","year":"2023","journal-title":"Annu Rev Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e70069","DOI":"10.3390\/ijms231911740","article-title":"Cytokine storm-definition, causes, and implications","volume":"23","author":"Jarczak","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70069","article-title":"Cytokine release syndrome in solid tumors","volume":"131","author":"Synnott","year":"2025","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-801238-3.65801-4","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.929572","article-title":"The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment","volume":"13","author":"Aguilar-Cazares","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2014.112813","article-title":"The role of inflammation, iron, and nutritional status in cancer-related anemia: Results of a large, prospective, observational study","volume":"100","author":"Macci\u00f2","year":"2015","journal-title":"Haematologica"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1804281","article-title":"Anemia of inflammation","volume":"381","author":"Ganz","year":"2019","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"274","DOI":"10.3390\/life15020274","article-title":"Thrombocytopenia in sepsis","volume":"15","author":"Setarehaseman","year":"2025","journal-title":"Life (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213510","article-title":"Current knowledge of thrombocytopenia in sepsis and COVID-19","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104088","article-title":"Anti-IL-6R Ab tocilizumab to treat paraneoplastic inflammatory syndrome of solid cancers","volume":"10","author":"Blay","year":"2025","journal-title":"ESMO Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.5.9497","article-title":"Tocilizumab","volume":"1","author":"Venkiteshwaran","year":"2009","journal-title":"MAbs"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2013.08.001","article-title":"Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums","volume":"43","author":"Navarro","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.026","article-title":"Targeting interleukin-6 signaling in clinic","volume":"50","author":"Kang","year":"2019","journal-title":"Immunity"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; What we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-020-00917-3","article-title":"Rational use of tocilizumab in the treatment of novel coronavirus pneumonia","volume":"40","author":"Zhang","year":"2020","journal-title":"Clin Drug Investig"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1762067\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:17:28Z","timestamp":1777954648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1762067\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":34,"alternative-id":["10.3389\/fonc.2026.1762067"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1762067","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"article-number":"1762067"}}